|
Vitamin D and Weight Loss Article
Presented at the Endocrine Society’s 91st Annual Meeting, June 10-13, 2009, Washington D.C. [OR14-5] Plasma Vitamin D: A Predictor of Subsequent Weight Loss Success.
SD Sibley, M Turner, C Earthman, Dept of Med, Univ of Minnesota, Minneapolis, MN; Dept of Food Sci and Nutrition, Univ of Minnesota, St Paul, MN
Background: Vitamin D deficiency is associated with obesity; the cause-effect nature of this relationship is not clear. Aim: To determine the temporal relationship between baseline plasma vitamin D and subsequent weight loss success.Materials/Subjects and Methods: Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations were measured in 38 obese individuals before and after an 11-week weight loss intervention consisting of a 750 calorie deficit/day from estimated total needs. Body composition and fat distribution were measured through dual-energy X-ray absorptiometry and computed tomography. Results: Plasma 25-hydroxyvitamin D and 1,25-dihydroxvitamin D were correlated with each other, both at baseline (R = 0.52, P<0.001) and post-weight loss (R = 0.44, P = 0.006). Separate regression analyses confirmed baseline 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D each predicted weight loss (P = 0.020; P = 0.015, respectively), and abdominal subcutaneous fat mass loss (P = 0.050; P = 0.038, respectively), but not lean body mass loss (R = -0.017, P = 0.613; R = -0.016, P = 0.352, respectively). Baseline Vitamin D and Subsequent Weight Loss 25-hydroxyvitamin D1,25-dihydroxyvitamin D coefSEPcoefSEP Weight loss (kg)0.1960.0810.020 0.1070.0420.015 Total lean body mass (kg)-0.0170.0330.613-0.0160.0170.352 Total body fat loss (kg)0.0850.0680.2200.0640.0350.074 Abdominal fat loss (kg)0.0560.0330.0980.0380.0170.033 Abdominal SQ fat loss (kg)0.0500.0250.0500.0280.0120.038 Adjusted for gender
Conclusions: Plasma vitamin D predicts subsequent weight loss, suggesting a potential role for vitamin D in promotion of weight loss, perhaps through effects on adipose metabolism. Studies are needed to confirm our findings and define underlying mechanisms.
Supported by NIH K23 Mentored Patient-Oriented Career Development Award No. DK-59445; University of Minnesota General Clinical Research Center Award #M01-RR00400.
Date: Thursday, June 11, 2009 Session Info: ORAL SESSION: CLINICAL - Therapeutic Interventions for Diabetes & Obesity (11:15 AM-12:30 PM) Presentation Time: 11:15 AM Room: 152AB
Unless otherwise noted, all abstracts are embargoed until the time of their presentation at ENDO 09. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to the start of ENDO 09. For additional information, please contact The Endocrine Society’s Public Affairs Department at 301-941-0240 or
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|